Wellington Management Group LLP Boosts Holdings in Artivion, Inc. (NYSE:AORT)

Wellington Management Group LLP boosted its position in Artivion, Inc. (NYSE:AORT - Free Report) by 2.9% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 1,656,264 shares of the company's stock after purchasing an additional 46,267 shares during the period. Wellington Management Group LLP owned about 3.95% of Artivion worth $44,090,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Louisiana State Employees Retirement System raised its position in Artivion by 3.1% in the second quarter. Louisiana State Employees Retirement System now owns 19,900 shares of the company's stock worth $510,000 after acquiring an additional 600 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Artivion by 0.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 301,992 shares of the company's stock worth $7,746,000 after purchasing an additional 2,018 shares during the period. RiverPark Advisors LLC purchased a new position in Artivion in the second quarter valued at approximately $55,000. nVerses Capital LLC bought a new position in Artivion during the second quarter valued at $28,000. Finally, Texas Permanent School Fund Corp increased its position in Artivion by 14.5% in the second quarter. Texas Permanent School Fund Corp now owns 39,063 shares of the company's stock worth $1,002,000 after buying an additional 4,934 shares during the last quarter. Hedge funds and other institutional investors own 86.37% of the company's stock.

Artivion Price Performance

NYSE:AORT traded down $0.28 during mid-day trading on Thursday, hitting $29.64. 56,754 shares of the stock traded hands, compared to its average volume of 226,159. The business's 50-day moving average price is $27.58 and its 200 day moving average price is $26.14. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The company has a market cap of $1.24 billion, a PE ratio of -1,496.00 and a beta of 1.75. Artivion, Inc. has a 12-month low of $16.48 and a 12-month high of $30.45.

Analysts Set New Price Targets

Several research firms have recently weighed in on AORT. Oppenheimer increased their price target on Artivion from $30.00 to $32.00 and gave the stock an "outperform" rating in a research note on Friday, November 8th. JMP Securities reiterated a "market outperform" rating and set a $33.00 target price on shares of Artivion in a research report on Tuesday. Needham & Company LLC reissued a "buy" rating and issued a $34.00 price target on shares of Artivion in a research report on Monday. Finally, Stifel Nicolaus upped their price target on shares of Artivion from $28.00 to $30.00 and gave the company a "buy" rating in a research note on Friday, September 13th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $31.80.

Insider Buying and Selling at Artivion

In other news, VP Andrew M. Green sold 7,618 shares of the stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $30.00, for a total value of $228,540.00. Following the transaction, the vice president now owns 33,503 shares of the company's stock, valued at $1,005,090. This represents a 18.53 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Amy Horton sold 12,430 shares of Artivion stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total transaction of $325,417.40. Following the sale, the chief accounting officer now directly owns 139,989 shares of the company's stock, valued at $3,664,912.02. This represents a 8.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 24,377 shares of company stock valued at $682,356 in the last three months. Company insiders own 8.10% of the company's stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.